Earnings call
Jagsonpal Pharmaceuticals Q1 FY27 earnings call: Jagsonpal Pharmaceuticals Limited expects to reach 1.5x the industry growth rate in the quarters to come
By DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person.
Transcript filed .
The company expects to reach 1.5x the industry growth rate in the quarters to come. The company grew by 9% in Q1 FY27; its Pharmarackdata growth was about 18.9% in the quarter, compared with industry growth of 11.6% in the period. The company was ranked amongst top 5 in 14 of its 15 brands and ranked No. 1 in 5 of these brands. The company completed a Rs.40 crores share buyback, which increased return on capital employed by another 340 bps.
The numbers management gave
Results
- The company grew by 9% in Q1 FY27; its Pharmarackdata growth was about 18.9% in the quarter, compared with industry growth of 11.6% in the period.
Show source
The strong performance is also reflecting in the Pharmarackdata where JPL grew by about 18.9% in the quarter as against the industry growth of 11.6% in the period.
- 9% sales growth in Q1 FY27 translated into 21% growth in operating EBITDA and 22% growth in net profits.
Show source
This 9% growth in sales has translated into a 21% growth in operating EBITDA as well as a 22% growth in net profits for the company.
- Between FY22 and FY26, Jagsonpal Pharmaceuticals Limited's EBITDA and PAT grew 2.5x, compounding at almost 25% annually, while its free cash flows increased 8x.
Show source
Between FY22 and FY26, our EBITDA and PAT has grown 2.5x, compounding at almost 25% annually, while our free cash flows have increased 8x.
- Power brand portfolio grew 19% in the quarter, compared with market growth of 16%.
Show source
Our power brand portfolio is also reflecting a growth of 19% versus the market growth of 16%.
- Operating EBITDA increased by around 21% to close to Rs.19 crores in Q1 FY27, with margins above 23%-plus, expanding by 240 bps.
Show source
Operating EBITDA increased by around 21%, standing close to Rs.19 crores, with margins above 23%-plus, expanding by 240 bps.
- PAT grew by 22% to Rs.13 crores in Q1 FY27, while margins improved by 176 bps to 16%.
Show source
PAT grew by 22% to Rs.13 crores, while margins improved by 176 bps to 16%.
Show 10 more statements
Results
- Return on capital (ROC) and return on equity (ROE) expanded by approximately 340 bps and 250 bps, respectively, in Q1 FY27.
Show source
Our capital efficiency also stands improved in ROC and ROE, expanding by approximately 340 bps and 250 bps respectively.
- Jagsonpal's cash conversion days dropped from 59-days to 22-days between FY22 to FY24.
Show source
Cash conversion days dropped from 59-days to 22-days.
- Gross margins in the business are about 65%, if not more.
Show source
Revenue from operations increased close to 9% year-on-year to Rs.82 crores, while gross profit grew over 10% to Rs.54 crores, with gross margins improving to 65%-plus.
Money and capital
- The company completed a Rs.40 crores share buyback, which increased return on capital employed by another 340 bps.
Show source
Alongside investing for growth, continuing our tradition for rewarding shareholders, we completed a Rs.40 crores share buyback which has strong positive impact on our already healthy return on capital employed by another 340 bps.
- Rs.40 crores share buyback was subscribed 3.67x and conducted at a premium of about 40% to the then prevalent market price.
Show source
The buyback, which was subscribed 3.67x was made at a premium of about 40% to the then prevalent market price.
- The company recouped almost 50% of its share buyback payout within the quarter.
Show source
Importantly, we have recouped almost 50% of this payout within this quarter, reflecting the strength of our business model as also discipline of execution.
- The company completed a Rs.40 crores buyback, half of which had been added back to closing cash-in-cash equivalents, maintaining a closing cash balance of Rs.170 crores.
Show source
Our commitment to enhancing shareholder value is reflected in the successful completion of our Rs.40 crores buyback, half of which has already been added back to the closing cash-in-cash equivalents, thereby maintaining a healthy closing cash balance of Rs.170 crores.
- Over the last four years, Jagsonpal Pharmaceuticals Limited generated over Rs.250 crores of operating cash, deployed towards strategic acquisitions including Yash Pharma for over Rs.90 crores, a dividend of over Rs.40 crores and a buyback of Rs.40 crores.
Show source
During this period, we have generated over Rs.250 crores of operating cash, which has been judiciously deployed towards strategic acquisitions, including Yash Pharma for over Rs.90 crores, as well as shareholders' returns through a dividend of over Rs.40 crores and buyback of Rs.40 crores.
- In April '26, the board recommended a dividend of 200%, including a special dividend of 75%; payment is subject to approval from shareholders at the ensuing AGM.
Show source
You may also recollect that the board recommended a dividend of 200%, including a special dividend of 75% in April '26.
- The total consideration for Jagsonpal Pharmaceuticals Limited's 85% stake in Aequitas Healthcare Private Limited would be Rs. 20.8 crores, funded from internal accruals of Jagsonpal.
Show source
I am pleased to share that we have successfully completed the acquisition of 85% stake in Aequitas Healthcare for a consideration of Rs.20.8 crores.
What it expects ahead
What management expects
- The company expects to reach 1.5x the industry growth rate in the quarters to come.
Show source
I do believe that we are now on track of getting our growth to 1.5x industry growth rate in the quarters to come.
- Aequitas is targeting around Rs.100 crores of business within two and a half years from now, looking at '28, '29 as the FY.
Show source
Amrut Medhekar: Aequitas alone, we are looking at around Rs.100 crores of business within two and a half years' time, starting from now.
- Aequitas is targeting upward of Rs.10 crores of EBITDA.
Show source
And we are certainly targeting upward of Rs.10 crores of EBITDA.
- The company expects the Aequitas Healthcare acquisition to start contributing meaningfully to its business from the second year onwards.
Show source
I am confident that this acquisition will start contributing meaningfully to JPL's business from second year onwards.
- The company expects its acquisition of Aequitas Healthcare to create value through commercial and operational synergies; integration is underway and the benefits are expected to become progressively visible in the coming quarters.
Show source
Integration is underway and we expect the benefits to become progressively visible in the coming quarters.
- The company expects cross-selling its brands through Aequitas's hospital brand reputation to help its growth engines gain entry into hospitals and deliver incremental value directly into EBITDA.
Show source
So, some of the Jagsonpal growth engines will also get a fresh entry into hospital which will give us incremental value which we expect to directly flow into our EBITDA.
Show 1 more statement
What management expects
- The company is planning to develop some new age brands with high usage in value per patient and volumes per ICU bed.
Show source
Third, very value-accretive thing that we are planning to do is some of the new age brands which have very high usage in terms of value per patient as well as in terms of volumes per ICU bed.
What it is building and selling
Segments
- The company was ranked amongst top 5 in 14 of its 15 brands and ranked No. 1 in 5 of these brands.
Show source
Today, our five brands rank #1 in respective molecules while 14 brands are among the top five.
- Aequitas has a longer working capital cycle than JPL, and Jagsonpal intends to improve Aequitas's cycle but not align it with JPL's.
Show source
We intend to improve it, but it will not get aligned with JPL.
Everything else said on the call
Group structure
- The company acquired a controlling stake in Aequitas Healthcare at an enterprise value of about Rs.25 crores; Aequitas had FY26 revenue of Rs.53 crores and provides Jagsonpal Pharmaceuticals Limited entry into the hospital segment through hospital formulary access, cross-selling and operating synergies.
Show source
A key milestone during the quarter was the acquisition of controlling stake in Aequitas Healthcare at an enterprise value of about Rs.25 crores.
- Aequitas expands Jagsonpal Pharmaceuticals Limited's network by almost 49 institutional medical representatives, access to over 1,000 hospitals and relationships across 4,000 specialty doctors.
Show source
It expands our network by almost 49 institutional medical representatives, access to over 1,000 hospitals and relationships across 4,000 specialty doctors.
- The promoters who retain a 15% stake in Aequitas Healthcare will continue to serve Jagsonpal Pharmaceuticals Limited and drive the business.
Show source
Second piece which I would like to clarify, since you mentioned it that the salaries will go away, but those promoters will continue to serve us as you have seen that we acquired only 85% and 15% still continues to be with those promoters and they will continue to drive the business which they have been doing.
- The company completed the acquisition of Aequitas in Q1 FY27.
Show source
I am proud to announce that Jagsonpal has completed the acquisition of Aequitas in this quarter.
People and governance
- Ms. Pallavi Dinodia Gupta stepped down from Jagsonpal Pharmaceuticals Limited's Board of Directors, citing personal commitments.
Show source
We acknowledge the valuable contribution of Ms. Pallavi Dinodia Gupta over the last four years, who stepped down citing personal commitments.
- Mr. Anil Kumar Matai joined Jagsonpal Pharmaceuticals Limited's Board as an Independent Director; he brings more than three decades of leadership experience across pharmaceutical and healthcare sectors.
Show source
We are delighted to welcome Mr. Anil Kumar Matai, who joins the Board as an Independent Director.
Show 1 more statement
Other
- The company is targeting people productivity upward of 2,50,000.
Show source
However, we are targeting upward of 2,50,000 in terms of people productivity.
What the company said on its earnings call, taken from its own transcript. Not advice.
Questions and answers
Question
Sajal Kapoor: Thank you for taking my question. Hi, team, good afternoon. I have three questions. First is, what will be the earliest evidence that Aequitas integration is working? And second is as you build the hospital business, what is the hardest capability to develop? What has surprised you the most since you acquired Aequitas?
Answer, amrut medhekar
Amrut Medhekar: To the last question, there has been no surprises. As you know, Sajal, that we are not a very, very large organization which can afford to take decisions and ignore few of the shortcomings which might be there in each business. So, therefore, a lot of due diligence has been done and accordingly the value fixation or enterprise value has also been decided. So, there have been no shocks or surprises for us post-acquisition. Second piece is, you asked me the evidence of first instance of success for Aequitas. I am pretty sure about it that numbers will speak maybe in the next two quarters. And you also asked, I think the second question was, what is success, what is the challenge for running a business?
Answer, amrut medhekar
You all know that, obviously, most of these hospital teams are also run by the private equities and there are a lot of pressure in terms of top line and bottom line growth for them also. So, they are hard negotiators. So, I think one skill which we need to learn as a team is how do we have a good proposition for the hospital which is making both the sides win-win. #2 is, it is a lean and thin team. You have very, very small 49-people on board which are completely focused on these corporate hospital chains. But most importantly, they bring with them on table very long and very strong and deep relationship with the hospitals, be it with the doctors, HCPs, or be it with the nursing staff, or be it with the administrative and purchase teams. So, I think that is going to be a lot of value Page 9 of 17 Jagsonpal Pharmaceuticals Limited July 30, 2026 addition for us also in Jagsonpal to learn from them and grow on that. So, it is more of a piggy ride for some of the Jagsonpal entry into hospital, besides the value that they have been already delivering.
Question
Sajal Kapoor: Sure. That is helpful, Amrut. I have got more questions. Perhaps I will rejoin the queue and thank you.
Answer, amrut medhekar
Amrut Medhekar: If I had to give you the numbers, I will give you in terms of percentages so that our internal numbers are not fully in public in terms of brand value. I can tell you what is coming in the public domain, which is Pharmarack numbers, which talks about a value of close to around Rs.46 crores is what it is showing in Pharmarack. Out of which, if I give you a breakup, Rs.34 crores is Maintane injections and Rs.13 crores is Maintane tablets. In terms of growth on both the SKUs, we are ahead of the molecule market growth. Second piece, I think if I have understood correctly and deciphered correctly, your question is whether it will change the portfolio picture. So, I think it is a very big brand for us. It is, I think, one of the top three brands for our company.
Answer, amrut medhekar
And therefore, if this brand fires well, it does well. Obviously, it is extremely value-accretive and extremely good for the organization, because our priority focus continues to be in the Gynecology. Ansh: Okay, sir. That is helpful. And so, what would be the PCPM, sir, for this quarter? And I am assuming this is what is leading our guidance, correct?
Answer, amrut medhekar
Amrut Medhekar: Exact PCPM numbers, I am sorry, Ansh, I would not be able to give that, but you can safely assume from our report because you have the top line and you have the number of people. But however, across businesses, there are different sets of PCPMs because we have four different verticals into prescription business, which is dermatology, which is gynecology, which is orthopedics, and we have Page 10 of 17 Jagsonpal Pharmaceuticals Limited July 30, 2026 GPCP. So, each vertical has a different PCPM. However, we are targeting upward of 2,50,000 in terms of people productivity. Ansh: Okay, sir. That is helpful. Thank you, sir.
Answer, amrut medhekar
Amrut Medhekar: Institutional tenders? Okay, I will give you the mix of products. So, primarily, since it is a hospital business, it is an ICU usage portfolio, which comprises predominantly antibiotics, including the latest generation antibiotics. Number two would be some of the volume enhancers. Number three would be some of the injectables which are used in perioperative usage, including a bit of anesthesia, a bit of nutrition, and the four species around the pain reliever and a little bit of anti-acid, which is used inside the hospital post-operative for the patient. So, these are the four broader buckets under which the product lies today. What was the second question, Neelam?
Answer, amrut medhekar
Amrut Medhekar: So, all of them are branded. I mean, since we do not participate in the government tenders, it is a purely corporate hospital chain pharma business. Neelam: Understood. And what would be the product concentration look like, like top-10 products, how much does it contribute to the Rs.53 crores sales?
Answer, amrut medhekar
Amrut Medhekar: Top 10 products would be anywhere upward of 50%, half of our total sales, and similarly, close to around 50-hospitals will contribute majority of our top line out of the total 1,000-hospitals that we cover. So, we have a lot of headroom to grow. Neelam: Got it. And in terms of Jagsonpal's existing products, cross-sell opportunities, could you identify which products would be most suitable for hospital cross-selling?
Answer, amrut medhekar
So, obviously, all our prescription brands which have very good equity outside the hospital, we would like to also have our presence inside these corporate hospitals, starting with Indocap, Endoreg, Maintane, and also Eukroma and KTC, all of them. Neelam: Got it. Okay. And generally, hospital businesses have longer working capital cycles. So, could you give us some sense around how is the working capital cycle for Aequitas currently and how are we looking at the overall Jagsonpal's lean working capital cycle going forward with this acquisition?
Answer, amrut medhekar
Amrut Medhekar: Yes. I mean, obviously, the productivity is also bigger there. The volume and ticket size is also bigger. Productivity is much larger in the hospital segment. So, the flip side is that how do you manage your credit cycle? So, we have a strategy in place, and we will be trying to align our strategy along with the Aequitas current credit terms that they have.
Answer, manish gupta
Manish Gupta: And Neelam, to add on to that, obviously, we cannot work with the same working capital cycle in Aequitas as we do in JPL. So, therefore, you will see that, a), it is a subsidiary route and not a BTA route that we have adopted. So, we do not want to mix up the two businesses in terms of practices. Both will have their own working capital cycle. Clearly, Aequitas working capital cycle is longer than JPL. We intend to improve it, but it will not get aligned with JPL. Neelam: Understood.
Answer, amrut medhekar
Amrut Medhekar: Aequitas alone, we are looking at around Rs.100 crores of business within two and a half years' time, starting from now. So, we are looking at '28, '29 as the FY. And I think we have given that in the board deck as well. And we are certainly targeting upward of Rs.10 crores of EBITDA. So, these are the two numbers that we are going to change here. Neelam: Got it. That is helpful.
Answer, amrut medhekar
Amrut Medhekar: I am not able to fully decipher it. The brand is doing well internally for us. But, if your question is that it is going to have a resounding effect on the portfolio? Then of course, yes, the way currently it is performing. But other brands are also doing reasonably well. So, you look at Metadec, you look at Lycored, you look at Equirex, you look at Divatrone, all the brands, including Endoreg or Pru. These brands are also doing better than the market for sure.
Answer, amrut medhekar
However, as I said that these are only small steps. The growth is yet to pick up and we expect that this momentum will only get stronger in the coming quarters, because these are all prescription brands. And growth of prescriptions over a period of time, it always depends on the new patient's journey, stickiness to the prescription which doctors prescribe. But most important is how do you get the brand loyalty from the prescriber community itself. Harshil: Okay, sir. Thank you.
Question
Vansh Gupta: Hi, sir. Thank you for the opportunity. So, sir, can you just please share what are some of the key hospital chains in which Aequitas is currently empanelled, and that you believe will be key drivers of your growth that you envisage for the next few years, and also the geographies in which these hospitals are located?
Answer, amrut medhekar
Amrut Medhekar: This is Pan India presence. Predominantly, all the top corporate hospital chains in our deck that we shared yesterday, it contains the names of those hospitals as well. The top six hospitals are, of course, Max, Manipal, Vedanta, Cloudnine, Rainbow, and also, we have Aster DM as well.
Question
Vansh Gupta: So, in the prior quarters, I believe the management had hinted at some first-in-India or breakthrough molecule pipeline. Can you please shed some light on the developments on the same if you have any?
Answer, amrut medhekar
Amrut Medhekar: No, we never mentioned this. I do not recall this in the earlier call if it has been discussed. But obviously, we are looking at some of the opportunities wherein we are able to get first-in-India opportunity in the available basket of our therapies, which is gynae, ortho or derma. If we are able to get first to launch opportunity, great. Or otherwise, at least in the first wave of launch, which may be five companies or select 10-companies only, we would like to be part of that.
Question
Vansh Gupta: And are there any such products under development for this year, sir?
Answer, amrut medhekar
Amrut Medhekar: This quarter, sir, we have been able to launch one product, which is among the first wave of launches. We expect one more such opportunity in the current quarter to happen.
Question
Sajal Kapoor: Yes, thanks again. It is a bookkeeping question, maybe related to working capital. I see a pattern. What execution habits changed after FY24 that unlock such a step change in working capital? I mean, working capital has improved dramatically since FY24. So, I am not taking hospital acquisition into consideration obviously. I am just trying to understand what has changed in the operating system to make such a dramatic improvement in net working capital? Page 14 of 17 Jagsonpal Pharmaceuticals Limited July 30, 2026 Amrut Medhekar: Our practices now are in line with the best in the industry in terms of collections.
Answer, amrut medhekar
That is what we have kind of ensured. And therefore, it is reflecting in the quality of business. Fundamentally, it is all about debtor collection that makes the difference in working capital. I mean, all others are important, but collecting money on time is what really matters as far as working capital is concerned. And here now we are in line with the best in the industry.
Question
Sajal Kapoor: No, I appreciate that, Manish. See, the quality of business was good in 2024 as well. So, I am just looking at the screener data. You may be tracking it slightly differently. But take the rate of change as an example. So, the debtor days were 19-days in 2024 and they are largely similar; 2025 was 18- days. 2026 was 22-days, so, again, in that ballpark of 20-days, give or take. Inventory days has improved from 68-days in 2024, we dropped to 51- days. So, that is positive, thumbs up. Payable days, I think, has gone worse actually. So, that is, I mean, again, 35-days versus 40-days, same ballpark. The material improvement that is happening is happening in the cash conversion cycle
Answer, amrut medhekar
Amrut Medhekar: So, two major changes which Sajal you highlighted is in terms of value. You look at it, value contribution is primarily from the part of inventory control.
Question
Sajal Kapoor: Say that again, Amrut. I did not quite catch that.
Answer, amrut medhekar
Amrut Medhekar: The material change is primarily happening because of the inventory control. While our collection cycles have continued to be same in spite of organically growing the business, yet our collection cycles have only become stringent. And number three, of course, there is a debtor control, which is much, much better in terms of any overdues in the market. And the last piece that possibly is working for us is creditors I think.
Answer, manish gupta
Manish Gupta: We are paying on time. I mean, now the very clear diktat is same day payment as per due date. There is not a single day extra. So, Sajal, I think if you look at the data, our larger dip in working capital came between FY22 to FY24. Cash conversion days dropped from 59-days to 22-days. Thereafter, yes, it has gone down, but now numbers are so small that they feel extrapolated, but actual real benefit came between FY22 to FY24.
Question
Sajal Kapoor: And Manish, is the digital transformation you took about a year or maybe two years back, is that also contributing, because it may have been a paper-based system, manual tracking, and now we have better analytics and digitization is kind of yielding the results that you might have expected?
Answer, manish gupta
Manish Gupta: Sajal, I will partly have but Amrut respond to this, but my own experience is you cannot attribute improvements to single factors in the kind of industry we operate in. There are hundreds of initiatives Page 15 of 17 Jagsonpal Pharmaceuticals Limited July 30, 2026 going on across all the firms, and each one of them matter. Individually, there is no one which is bigger than the other. Every initiative, as Amrut mentioned in his speech, these are all things that have been initiated, digital is one of them that also is contributing, but there is no singular parameter which has dramatically changed our way of doing business. Amrut, do you want to add?
Answer, amrut medhekar
Amrut Medhekar: No, I think, Sajal, it is very difficult to list out, but there has been also a classification of importance of specialty, therapy, which molecules are delivering more delta in terms of market, how our brands are tracking, what is our strength in which specialty, what should be the increased frequency of doctor visits, customer visits, in what calendar cycle we should be doing it, what will be our order cycle, how do we split up the orders so that there are no bend days at the end of any quarter, so you have split up order for each stock case. So, a lot of discipline has been worked upon. These are all granular, very small little things, Sajal. But eventually I think these will create a very strong foundation for the organization where the growth is profitable and sustainable growth.
Question
Anubhav Mukherjee: Sir, I just have one question. The gross margin profile for Aequitas seems to be low for a completely branded business and also much lower than our business. So, can you share some colour on why is that?
Answer, amrut medhekar
Amrut Medhekar: For a hospital business, it will be like this. The margins will be much thinner versus a branded prescription business, because there you have doctors choice towards or buyers towards a particular brand due to its name, image, quality associated with it over a long-term use. But in hospital settings, it is more than the brand, it is always the price that comes first. Obviously, brand becomes number two there. So, largely if you look at, all the large organizations will have similar kind of quality, all the large companies and good companies, but what makes the difference in terms of which brand they will have choice to stock would be the price. And therefore, your margins always come under pressure while dealing with the corporate chains. So, you cannot have a comparison between these two business models.
Answer, amrut medhekar
They are independent. As Manish has said, this will continue to operate as a subsidiary. We are making efforts to improve the gross margins as well with some identified products where you are able to charge a big premium from the market being a little more innovative, being a little more novel in terms of your entry point. I hope it answers partially to your question.
Show 2 more questions
Question
Anubhav Mukherjee: Yes, sure. And sir, the margin improvement for this business like Aequitas will come from like you are alluding to like gross margin improvement, but will it come mainly from that gross margin improvement or like productivity gain and operating leverage? Page 16 of 17 Jagsonpal Pharmaceuticals Limited July 30, 2026 Amrut Medhekar: This will happen.
Answer, amrut medhekar
So, one is, of course, productivity increase will continue to be our objective. But, at the same time, we are looking at a product mix improvement. So, the products which will have higher gross margin, that is where we are going to be more aggressive. That will be our primary purpose. Number two, we have already pre-identified and pre-populated some of the innovative products where you have a differential delivery or a differential, I will say, entry point where you will be able to charge a little more premium as compared to your current market. And therefore, in the longer run, I feel slowly and gradually these gross margins will also go up. Now, it all depends on how quickly we are able to unfold it and execute it on the field.
Answer, amrut medhekar
So, this is too early. I think this is not even the first month. I think we should be able to convey to you more clearer in the coming quarters.
Question
Anubhav Mukherjee: Got it. Thanks. That is all from my side.
Answer, nirav vora
Nirav Vora: Thank you, all participants, for your valuable questions and engagement. We appreciate your interest in Jagsonpal. Should you have any further queries or any requirement of additional information, please do not hesitate to contact our investor relationship team at Go India Advisors. We remain committed to engaging with you all, fostering transparent communication as we continue advancing our objectives of creating value for our stakeholders. Thank you once again for your participation and wishing you a very good evening.
Questions about this call
- When was the Jagsonpal Pharmaceuticals Q1 FY27 earnings call transcript filed?
- Jagsonpal Pharmaceuticals filed the transcript with the exchange on 4 Aug 2026. This page is built from that transcript.
- What does this page list?
- 32 statements from the transcript across 7 topics, 24 of them with a figure. Each statement is shown with the transcript sentence it came from.
- Are the analysts' questions included?
- Yes. 12 questions and management's answers are listed in the order they were asked, as the transcript prints them.
- Who wrote this page?
- DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person. How it is made, and what it leaves out, is on the method page linked from the byline.